This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Cirrhosis or Portal Hypertension
and you are
between 18 and 75
years old
The primary goal of this phase is to monitor the long-term effects.
The treatment is already on the market.
Show me locations

The purpose

The aim of this study is to investigate the effects of spironolactone on liver fibrosis progression and portal hypertension in patients with compensated cirrhosis. The patients were nonrandomized according to the medical conditions determined by the physicians, in 3 arms (spironolactone start from 40mg once daily and increase every week with a maximum dose as 100mg once daily, carvedilol start from 6.25mg once daily and increase to 12.5mg once daily in next week if being tolerated, spironolactone in combination with carvedilol: spironolactone is added when carvedilol has reached the most tolerated dose). Portal pressure gradient by virtual hepatic venous pressure gradients based on enhanced CT, and liver elasticity by Fibroscan Medical Device are documented at baseline level and every six months after the treatment. Changes in serum fibrosis markers and liver function are monitored before and every 3 months after the treatment.

Provided treatments

  • Drug: Spironolactone Pill
  • Drug: Carvedilol
  • Drug: Spironolactone and Carvedilol

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02907749. The sponsor of the trial is Changqing Yang and it is looking for 60 volunteers for the current phase.
Official trial title:
Effects of Spironolactone on Fibrosis Progression and Portal Hypertension in Patients With Compensated Cirrhosis